Warning for lopinavir/ritonavir oral solution

The US Food and Drug Administration has notified health care practitioners that severe, possibly fatal, health problems have been reported in babies who have received lopinavir/ritonavir oral solution.

The US Food and Drug Administration (FDA) has notified health care practitioners that severe, possibly fatal, health problems have been reported in babies who have received lopinavir/ritonavir oral solution.

Lopinavir/Ritonavir oral solution is an antiviral medication containing alcohol and propylene glycol that is used in combination with other antiretroviral drugs to treat human immunodeficiency virus (HIV-1) infection .

Preterm neonates have a decreased ability to eliminate propylene glycol, which could lead to adverse events including serious heart, kidney, and respiratory problems.